VolitionRx plans European launch of CRC screening product — 4 insights

VolitionRx is planning the European launch of its CRC screening product in 2018.

Here's what you should know:

1. The company is in the process of validating two clinical trials, in an attempt to earn a CE Mark.

2. If successful, the company plans to launch a frontline CRC screening product sometime in 2018.

3. Volition's CEO Cameron Reynolds said in a release the product launch will be the company's "largest near-term opportunity." He added the European market has 150 million-plus residents of screening age.

4. Volition is in the midst of a U.S.-based study as well. The company is conducting a 13,500 patient study with the Early Detection Research Network and Rockville, Md.-based U.S. National Cancer Institute.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast